Prospective clinical study of moxibustion in the treatment of Parkinson's disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2000002995

Enrollment

Unknown

Registered

2020-02-11

Start date

2021-08-10

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Interventions

experimental group:standard treatment, and Moxibustion

Control group:standard treatment and sham moxibustion

002001

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) All enrolled patients in accordance with diagnostic criteria. (2) Patients with Hoehn-yahr (H-Y) grade 1 to 3. (3) Patientsage under 70 years. (4) Duration of Parkinson over 6 months. (5) Patients take pasta hydrazine tablets at least 30 daysand the medication regimen was not adjusted. (6) Patients sign informed consent.

Exclusion criteria

Exclusion criteria: (1) Various secondary Parkinson's syndrome, Parkinson's syndrome, and Hoehn-yahr (H-Y) > 3. (2) Patients with dementia and mental disorders and unable to communicate and cooperate. (3) Patient has a history of severe brain trauma and brain surgery. (4) Patients have severe systemic organic diseases such as heart, lung, liver, kidney, endocrine diseases and metabolic disorders. (5) Patients cannot receive moxibustion.

Design outcomes

Primary

Measure	Time frame
MDS-UPDRS scale;SCL-90;BPI;EEG;EMG;PDQ-39;RS-fMRI;FSS;Wexner;PDSS;	—

Countries

China

Contacts

Public ContactZhu Meiling

Traditional Chinese Medicine Hospital of Bao'an District, Shenzhen

48506106@qq.com+86 13312996033

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026